Monika Yadav

Monika Yadav

Auto-generated profile, based on publicly available information

Monika Yadav

Center for Molecular Oncology and Cellular Therapeutics (MOCT), Children’s Mercy Research Institute (CMRI) , Kansas City, Missouri

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2026 in Neuro-Oncology
Verified
Journal Article
Open access
DADavid Akhavan
David Akhavan
MYMonika Yadav
Monika Yadav
SSSiddharth Subham
Siddharth Subham
John JeppsonJohn Jeppson
John Jeppson
OTOmar Tinoco
Omar Tinoco
VYVivekanand Yadav
Vivekanand Yadav
Background: Diffuse hemispheric glioma (DHG), H3 G34-mutant, is a highly aggressive and fatal pediatric brain tumor, with a median survival of only ∼18 months and no effective targeted therapies. While chimeric antigen receptor (CAR) T cell therapy has shown success in B-cell leukemia and promise in other pediatric central nervous system tumors, it has not yet been evaluated explicitly in preclinical or clinical models of DHG. B7-H3 (CD276), a tumor-associated antigen overexpressed in pediatric brain tumors, represents a promising target for immunotherapeutic intervention in DHG. Here, we present the first preclinical evaluation of B7-H3-directed CAR T cell therapy in DHG. Methods: We evaluated B7-H3 expression in specimens from DHG patients and patient-derived cell lines. Two B7-H3-targeted CAR constructs were generated and evaluated for antigen-specific activation, cytokine production, exhaustion, and cytotoxicity in vitro. Therapeutic efficacy was assessed in multiple orthotopic DHG xenograft models, followed by multiplex immunofluorescence and serum cytokine profiling. Results: B7-H3 was highly expressed in DHG tumors and cell lines, but at minimal levels in normal brain tissue. B7-H3 CAR T cells demonstrated potent, antigen-specific cytotoxicity against DHG cells, with negligible activity against B7-H3-knockout DHG cells. In vivo, the intratumoral administration of B7-H3 CAR T cells led to significant tumor regression and a substantial extension of survival in 3 DHG mouse models, with durable tumor eradication. Conclusion: This study provides preclinical evidence supporting B7-H3 CAR T cell therapy as a highly effective immunotherapeutic strategy for DHG. Our findings support B7-H3 as a compelling immunotherapeutic target for DHG, laying the groundwork for clinical translation.